Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of antibiotic-resistant bacteria poses a significant threat to global health, rendering many existing antibiotics ineffective. Traditional antibiotic development struggles to keep pace with the rapid evolution of pathogens, leading to a critical need for new strategies.
Solution
Evolvere BioSciences employs artificial intelligence and co-evolutionary modeling to design novel antibiotics that can overcome bacterial resistance mechanisms. Their approach simulates the evolutionary arms race between bacteria and antibiotics, allowing them to predict and preempt resistance development. By understanding how bacteria evolve in response to drugs, Evolvere BioSciences can create antibiotics that remain effective over longer periods. This proactive strategy aims to provide a sustainable solution to the growing problem of antibiotic resistance.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and government agencies involved in antibiotic development and combating antimicrobial resistance.
Features
- AI-driven co-evolutionary models to predict and preempt bacterial resistance
- In silico drug design to identify novel antibiotic candidates
- High-throughput screening to validate antibiotic efficacy against resistant strains
- Optimization of drug candidates for improved potency and pharmacokinetic properties